First entomological documentation of Aedes (Stegomyia) albopictus (Skuse, 1894) in Algeria  by Izri, A. et al.
[12,13], but there are no reports on ocular infections with
other insect-borne microsporidia.
The common environmental sources of microsporidia
include ditch water and other stagnant water bodies. Three
common species of microsporidia that infect humans have
been detected in these water samples [1,14]. The increased
incidence of microsporidia during the monsoon may be due
to contamination of water with microsporidia or the
increase in the insect population in this season.
The relatively small number of cases and the retrospective
nature of the study limit the strength of our conclusions. A
prospective study would be required to identify the sources
and modes of transmission of microsporidial keratitis and
the species of microsporidia responsible for infection.
Transparency Declaration
The study was funded by Hyderabad Eye Research Founda-
tion. The authors declare the absence of competing interests.
References
1. Dowd SE, Gerba CP, Pepper IL. Conﬁrmation of human pathogenic
microsporidia Enterocytozoon bieneusi, Encephalitozoon intestinalis and Vit-
taformae cornea in the water. Appl Environ Microbiol 1998; 64: 3332–
3335.
2. Joseph J, Vemuganti GK, Sharma S. Microsporidia: emerging ocular
pathogens. Indian J Med Microbiol 2006; 23: 80–91.
3. Weber R, Bryan RT, Schwartz DA, Owen RL. Human microsporidial
infections. Clin Microbiol Rev 1994; 7: 426–461.
4. Sridhar MS, Sharma S. Microsporidial keratoconjunctivitis in a HIV-
seronegative patient treated with debridement and oral itraconazole.
Am J Ophthalmol 2003; 136: 745–746.
5. Kunomoto DY, Sharma S, Garg P, Gopinathan U, Miller D, Rao GN.
Corneal ulceration in the elderly in Hyderabad, South India. Br J Oph-
thalmol 2000; 84: 54–59.
6. Raynaud L, Delbac F, Broussolle V et al. Identiﬁcation of Encephalato-
zoon intestinalis in travelers with chronic diarrhea by speciﬁc PCR
ampliﬁcation. J Clin Microbiol 1998; 36: 37–40.
7. Joseph J, Sridhar MS, Murthy S, Sharma S. Clinical and microbiological
proﬁle of microsporidial keratoconjunctivitis in Southern India. Oph-
thalmology 2006; 113: 531–537.
8. Das S, Sharma S, Sahu SK, Nayak SS, Kar S. New microbial spectrum
of epidemic keratoconjunctivitis: clinical and laboratory aspects of
outbreak. Br J Ophthalmol 2008; 92: 861–862.
9. Franzen C. Microsporidia: a review of 150 years of research. Open
Parasitol J 2008; 2: 1–34.
10. Mathis A, Weber R, Deplazes P. Zoonitic potential of the microspo-
ridia. Clin Microbiol Rev 2005; 18: 423–445.
11. Didier ES, Stovall ME, Green LC, Brindley PJ, Sestak K, Didier PJ. Epi-
demiology of microsporidiosis: source and modes and transmission.
Vet Parasitol 2004; 126: 145–166.
12. Coyle CM, Weiss LM, Rhodes LV et al. Fatal myositis due to the mi-
crosporidian Brachiola algerae, a mosquito pathogen. N Engl J Med
2004; 351: 42–47.
13. Visveswara GS, Belloso M, Moura H et al. Isolation of Nosema algerae
from the cornea of an immunocompetent patient. J Eukaryot Microbiol
1996; 46: 10S.
14. Sparfel JM, Sarfati C, Liguory O et al. Detection of microsporidia and
identiﬁcation of Enterocytozoon bieneusi in surface water by ﬁltration
followed by speciﬁc PCR. J Eukaryot Microbiol 1997; 44: 78S.
First entomological documentation of
Aedes (Stegomyia) albopictus (Skuse, 1894)
in Algeria
A. Izri1, I. Bitam2 and R. N. Charrel3
1) Parasitologie-Mycologie, APHP, Hoˆpital Avicenne, Bobigny, France,
2) Entomologie Me´dicale, Institut Pasteur d’Alger, Alger, Alge´rie and
3) Unite´ des Virus Emergents, UMR190, Institut de Recherche pour le
De´veloppement, Universite´ de la Me´diterrane´e, Marseille, France
Abstract
In August 2010, during an entomological programme targeting
sandﬂies, in the region of Larbaa-Nath-Iraten, Wilaya of Tizi-
Ouzou (Algeria), a female Aedes albopictus was trapped alive and
partially engorged. To our knowledge, this is the ﬁrst report of
Ae. albopictus in Algeria and more widely in the Maghreb.
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During an entomological surveillance programme aimed at
the collection of sandﬂies, in the region of Larbaa-Nath-Ira-
ten, Wilaya of Tizi-Ouzou (Algeria), from 2 to 8 August
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2010, a female Aedes albopictus was trapped alive and partially
engorged. To our knowledge, this is the ﬁrst report of Ae.
albopictus in Algeria and more widely in the Maghreb.
Ae. albopictus, also know as the Asian Tiger mosquito, is
an effective vector for a large number of arboviruses, among
which are chikungunya and dengue viruses [1]. Historically,
Ae. albopictus is a zoophilic forest species indigenous to Asia.
First disseminations east to the islands of the Paciﬁc Ocean
and west to the islands of the Indian Ocean occurred during
the 19th century [2]. The most dramatic expanding phenom-
enon started in the 1980s and has not stopped yet. It
invaded Europe (Albania in 1979) [3], North America (Texas
in 1985) [4] and South America (Brazil in 1986) [5]. In the
early 21st century, apart from Asia, Ae. albopictus was
installed from the US to Argentina, in Central Africa and in
Western Europe [1].
Ae. albopictus is a day-biting mosquito with a generalist
behaviour allowing rapid adaptation to a large variety of envi-
ronments in both tropical and temperate areas [6]. It is well
adapted to the peridomestic environment, where it feeds on
humans and domestic animals and lay eggs in a variety of natu-
ral and artiﬁcial water holding containers [7]. Ae. albopictus
might be less adapted than Ae. aegypti to extreme urbanized
environments such as megacities, but it ﬂourishes in residen-
tial environments characterized by gardens and swimming
pools. It has been argued that Ae. albopictus may be a less efﬁ-
cient vector than Ae. aegypti for arboviral diseases. However,
the rationale is not so clear because Ae. albopictus has a
marked preference for humans over animals [8]. Recent ﬁeld
evidence demonstrates that, regardless of the competence of
Ae. albopictus, its recent presence in Italy has resulted in an
epidemic of chikungunya affecting several hundreds of inhabit-
ants. Similarly, the combined presence of the vector together
with imported cases of both dengue and chikungunya in
south-eastern France has resulted in the ﬁrst appearance of
autochthonous cases, two cases of dengue and two cases of
chikungunya [9,10]. Interestingly, a total of 120 imported
cases of dengue and only two imported cases of chikungunya
have been reported and laboratory documented during the 5-
month surveillance period during summer 2010 [10].
In our entomological study in Algeria, the fact that only
one female Ae. albopictus was trapped can be easily explained
by the nature itself of the mission, which targeted sandﬂies
and not mosquitoes. Trapping was performed during the
night, and not daily, using CDC traps, which are notoriously
not the most appropriate for Ae. albopictus. For the same
reason, breeding sites were not searched for in this study.
Because this female Ae. albopictus was trapped during the last
day of the campaign, it was not possible to extend ﬁeld work
towards measuring densities.
During the last decade, Aedes albopictus has implanted
itself in most of the countries north of the Mediterranean
(Spain, France, Italy, Greece, Croatia, Bosnia, Albania and
Montenegro) [11]. However, the presence of Ae. albopictus
was not acknowledged in the countries south of the Medi-
terranean, including those forming the Maghreb region.
We report here the ﬁrst record, to our knowledge, of Ae.
albopictus in Algeria. The fact that it was partially engorged
and trapped alive indicates that it was active, and further sup-
ports the presence of Ae. albopictus in Algeria. A single report
of Ae. albopictus in Algeria, in the absence of documented
human cases of dengue or chikungunya, suggests that the den-
sity of Ae. albopictus in Algeria is currently extremely low.
However, as recently demonstrated in southern France, the
risk of dissemination of Ae. albopictus, possibly resulting in Ae.
albopictus-borne viral diseases such as dengue and chikungu-
nya, should be seriously considered. An airport and harbour
are located 120 km away from the trapping area; however,
there is an intense road trafﬁc that may be an important
determinant of the presence of Ae albopictus in the region.
These data clearly indicate that, irrespective of the com-
petence of Ae. albopictus for dengue and chikungunya viruses,
the risk of outbreak due to arboviruses vectored by this
insect is real and must be taken into consideration and given
extreme attention. Rapid mobilization of entomologists is
necessary to conﬁrm and to further investigate the area(s)
colonized by the Ae albopictus in Algeria, and in other coun-
tries of the Maghreb. As recently pointed out [11], in all
countries where Ae. albopictus circulates there is an urgent
neeed to organize surveillance at medical, veterinary and
entomological levels, to prepare to combat the mosquito,
and to mount detection strategies aimed at rapid and trustful
diagnostics so that countermeasures can be applied rapidly.
Acknowledgements
This work was supported by the French Research Agency
(ANR) through the PhleboMED project.
Transparency Declaration
The authors have no conﬂicts of interest to declare.
References
1. Gratz NG. Critical review of the vector status of Aedes albopictus.
Med Vet Entomol 2004; 18: 215–227.
CMI Research Notes 1117
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1114–1122
2. Knudsen AB. Global distribution and continuing spread of Aedes albo-
pictus. Parassitologia 1995; 37: 91–97.
3. Adhami J, Reiter P. Introduction and establishment of Aedes (Ste-
gomyia) albopictus Skuse (Diptera: Culicidae) in Albania. J Am Mosq
Control Assoc 1998; 14: 340–343.
4. Sprenger D, Wuithiranyagool T. The discovery and distribution of
Aedes albopictus in Harris County, Texas. J Am Mosq Control Assoc
1986; 2: 217–219.
5. Forattini OP. Identiﬁcation of Aedes (Stegomyia) albopictus (Skuse) in
Brazil. Rev Saude Publica 1986; 20: 244–245.
6. Rai KS. Aedes albopictus in the Americas. Annu Rev Entomol 1991; 36:
459–484.
7. Hawley WA, Reiter P, Copeland RS, Pumpuni CB, Craig GB Jr. Aedes
albopictus in North America: probable introduction in used tires from
northern Asia. Science 1987; 236: 1114–1116.
8. Lambrechts L, Scott TW, Gubler DJ. Consequences of the expanding
global distribution of Aedes albopictus for dengue virus transmission.
PLoS Negl Trop Dis 2010; 4: e646.
9. Gould EA, Gallian P, De Lamballerie X, Charrel RN. First cases of
autochthonous dengue fever and chikungunya fever in France: from
bad dream to reality!. Clin Microbiol Infect 2010; 16: 1702–1704.
10. La Ruche G, Souare`s Y, Armengaud A et al. First two autochthonous
dengue virus infections in metropolitan France, September 2010. Euro
Surveill 2010; 15: 19676.
11. Paupy C, Delatte H, Bagny L, Corbel V, Fontenille D. Aedes albopic-
tus, an arbovirus vector: from the darkness to the light. Microbes
Infect 2009; 11: 1177–1185.
b-D-Glucan kinetics for the assessment of
treatment response in Pneumocystis jirovecii
pneumonia
J. Held1 and D. Wagner2
1) Institute of Medical Microbiology and Hygiene and 2) Centre for
Infectious Diseases and Travel Medicine and Centre of Chronic
Immunodeﬁciency, University of Freiburg, Freiburg, Germany
Abstract
Serum (1ﬁ3)-b-D-Glucan (BG) is a biomarker for Pneumocystis
jirovecii pneumonia (PJP). However, information concerning its
usefulness for monitoring the clinical course is lacking. We con-
ducted a retrospective study to investigate whether consecutive
BG-measurements can be used to assess treatment response in
PJP. Analysis of sera from 18 patients during PJP therapy shows
that decreasing BG-levels strongly correlate with a favourable
clinical course. In contrast, increasing BG-levels were associated
with treatment failure or fatal outcome is only 44% of patients.
As a consequence, BG-kinetics might be used to conﬁrm treat-
ment success but seem to be of limited value for the identiﬁca-
tion of treatment failure.
Keywords: b-D-Glucan, follow-up, kinetic, Pneumocystis jirovecii
pneumonia, therapy success
Original Submission: 3 November 2010; Revised Submis-
sion: 16 December 2010; Accepted: 16 December 2010
Editor: E. Roilides
Article published online: 22 December 2010
Clin Microbiol Infect 2011; 17: 1118–1122
10.1111/j.1469-0691.2010.03452.x
Corresponding author: J. Held, Institute of Medical Microbiology
and Hygiene, University of Freiburg, Hermann-Herder-Str. 11, 79104
Freiburg, Germany
E-mail: juergen.held@uniklinik-freiburg.de
Early detection and effective therapy is vital in reducing mor-
tality resulting from Pneumocystis jirovecii pneumonia (PJP).
Resistance to ﬁrst-line therapy exists, and because of the
inability to grow the fungus in vitro, there are currently no
reliable methods for the assessment of P. jirovecii antimicro-
bial sensitivity [1,2]. Thus, except for clinical presentation,
improvement of radiological ﬁndings, and non-speciﬁc param-
eters such as the arterial partial pressure of oxygen or lac-
tate dehydrogenase (LDH) levels, no objective tests for
monitoring of treatment efﬁciency exist.
(1–3)-b-D-Glucan (BG) is a cell wall component of P. ji-
rovecii and of various other fungi. BG is released into the
serum during the course of an invasive infection. Emerging
data from recent years have pointed to serum BG measure-
ment as a promising new tool for the diagnosis of PJP [3–5].
However, results concerning its usefulness for following the
patient’s clinical course are missing.
To investigate whether consecutive serum BG measure-
ments can be used to assess treatment response, we retro-
spectively examined all patients presenting at our hospital
between January 2003 and July 2010 with conﬁrmed PJP and
for whom ﬁve or more sera during follow-up were available.
Conﬁrmed PJP required the identiﬁcation of P. jirovecii by im-
munostaining (DETECT IF test; Axis Shield Diagnostics Lim-
ited, Dundee, UK) and/or detection of P. jirovecii DNA by
PCR of bronchoalveolar lavage ﬂuid (BALF), as well as a typi-
cal clinical presentation. P. jirovecii touchdown PCR was per-
formed as previously described [6]. All ampliﬁcation
products were sequenced and conﬁrmed to be parts of the
P. jirovecii mitochondrial large-subunit rRNA gene. Clinical
presentation was considered to be typical if pulmonary inﬁl-
trates compatible with PJP were present and if at least four
1118 Clinical Microbiology and Infection, Volume 17 Number 7, July 2011 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1114–1122
